CLINICAL STUDY

Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs

Patrick Petrossians, Liliane Borges-Martins, Consuelo Espinoza², Adrian Daly, Daniela Betea, Hernan Valdes-Socin, Achille Stevenaert¹, Philippe Chanson² and Albert Beckers

Departments of Endocrinology and ¹Neurosurgery, CHU de Liège, Sart Tilman, B-4000, Liège, Belgium and ²Department of Endocrinology, Hôpital Bicêtre, 78 Rue Du General Leclerc, F-94275, Le Kremlin-Bicêtre, France

(Correspondence should be addressed to A Beckers; Email: albert.beckers@chu.ulg.ac.be)

Abstract

Introduction: Invasive GH-secreting pituitary adenomas are rarely cured by surgery and although long-term therapy with somatostatin analogs (SSAs) may be employed, hormonal control is achieved in only 60% of cases. The impact of tumor debulking on subsequent control of acromegaly with SSAs has not been studied previously.

Methods: We studied retrospectively the response to SSA therapy in acromegalic patients before and after incomplete surgical tumor excision. A case review identified 24 acromegalic patients who had received SSA therapy for ≥ 1 month before and after gross total resection or debulking of adenomas. No patient received radiotherapy or combination treatment with SSAs and dopamine agonists during the study. GH and IGF-I responses to SSAs were recorded pre- and postoperatively. Postoperative SSA therapy was begun after a washout period of 1–3 months to assess the hormonal effects of the surgery alone.

Results: Before preoperative SSA treatment, 24/24 (100%) patients had elevated GH levels and IGF-I levels were elevated in 19/21 (90.5%) patients with recorded values. During preoperative SSA treatment, GH and IGF-I levels were normalized in 7/24 (29.2%) and 11/24 (45.8%) patients respectively. Following postoperative washout, GH was controlled in only 3/24 (12.5%) patients, while IGF-I was controlled in 8/19 (42.1%) patients with available data. During the second SSA treatment period, normal GH levels were seen in 13/24 (54.2%) patients, while IGF-I control was noted in 18/23 (78.3%).

Conclusion: Gross total tumor resection or debulking increases the likelihood of achieving biochemical disease control with SSAs in acromegalic patients with adenomas that were not amenable to complete surgical resection and in whom primary SSA therapy was unable to achieve good biochemical control.

European Journal of Endocrinology 152 61–66

Introduction

Chronic hypersecretion of growth hormone (GH) results in acromegaly, a disease with multiple complications, high long-term morbidity and increased mortality. Three classes of therapy are available for acromegaly: surgical, medical and radiological (1). For patients with microadenomas or uncomplicated macroadenomas, primary therapy is usually adenomectomy, commonly via the transsphenoidal approach. Patients often receive presurgical treatment with a somatostatin analog (SSA) in an effort to improve physical symptoms, to shrink tumors or to influence tumor morphology favorably. For acromegalic patients who are unfit for surgery, or in elderly patients with

mild symptoms, primary medical therapy may be advocated, usually with an SSA. The cure rate following surgery in acromegaly is approximately 50–70%; thus many patients who do not achieve surgical cure require subsequent medical or radiation therapy. There is some controversy about the primary treatment of acromegaly in patients with complicated tumors with a low potential for successful surgery (2). This is particularly true in adenomas with laterosellar extension or evidence of invasiveness. Many of these patients will receive SSA therapy in an effort to slow tumor growth and alleviate symptoms; however, the rate of therapeutic failure in normalizing all parameters in this group is significant (40–60%) (3–5). The impact of surgery on the hormonal response to SSAs has not

been studied previously in a series of acromegalic patients with difficult-to-resect tumors. Therefore, we performed a retrospective study of the GH and insulin-like growth factor-I (IGF-I) responses to SSAs before and after subtotal surgical tumor excision.

Patients and methods

Case records of acromegalic patients from two centers (University Hospital, Liège, Belgium and Bicêtre University Hospital, Le Kremlin-Bicêtre, France) were screened for subjects who had undergone transsphenoidal surgery and who were treated with SSAs before and after surgery. We identified patients who underwent either (i) tumor debulking of an unresectable tumor or (ii) gross total resection that did not lead to complete tumor excision (Table 1). All patients had to have clinically active acromegaly before and after surgery, and only patients for whom sufficient GH and IGF-I data were available during the pre- and post-surgical periods were included. Preoperative SSA treatment was given for at least 1 month in all patients, while postoperative SSA therapy lasted at least 3 months. Patients who received combination treatment with SSAs and dopamine agonists during the study period were excluded. No patient had received radiotherapy before or during the study period. To allow for an adequate washout period, post-surgical hormonal sampling was performed at least 30 days after surgery and the last

octreotide administration. Three patients were treated before surgery using long-acting SSAs (lanreotide and lanreotide autogel), and the post-surgical evaluation was done after a 3 month period in these patients.

GH and IGF-I measurements

GH and IGF-I were measured at four time points: t0: baseline data at diagnosis; t1: data during preoperative SSA treatment; ts0: data after surgery and SSA wash-out; ts1: data during postoperative SSA treatment.

The following hormonal values were selected: the basal GH value pre-SSA therapy, the lowest GH value obtained during SSA therapy and the corresponding IGF-I levels before and during SSA therapy. GH and IGF-I concentrations were measured using commercially available kits. 'Normal' GH cut-off values have been lowered in recent years, with the current literature favoring a value of 2 µg/L; thus we chose this threshold for our study (1). Due to the use of different assays, IGF-I values were expressed as a percentage of the upper limit of normal values, normalized for age and sex for each assay. Thus, the cut-off value for normalization of IGF-I was 100%.

Statistical analysis

The GH and IGF-I data showed the presence of outliers in the higher values of the samples. This deviation from a normal distribution of the samples was confirmed by

Table 1 Patient characteristics and treatment details.

Patient	Sex/age	Diameter	Invasion	Treatment	Dose	Duration (months)	Surgery	Immunohistology	Treatment	Dose	Duration (months)
1	M/36	17	—	Octr	300	4	1	GH, α-SU	Octr	300	2
2	F/39	32	L	Octr	300	1	2	GH, PRL	Octr	300	2
3	M/48	20	—	Octr	600	6	1	GH, PRL	Octr	300	4
4	M/34	26	—	Octr	900	3	1	GH, ACTH	Octr	1500	5
5	F/55	12	—	Octr	300	1	1	GH, PRL	Octr	200	6
6	F/42	25	—	Lanr	60	5	2	GH, PRL	Lanr	60	4
7	M/35	26	R	Octr	300	3	1	GH, PRL	Octr	300	1
8	F/62	18	L	Octr	300	5	1	GH	Octr	300	7
9	M/36	<10	—	Octr	1500	6	1	GH	Octr	400	3
10	M/38	15	—	Octr	1500	1	1	GH	Octr	300	4
11	M/44	23	L	Octr	300	5	2	GH	Octr	300	12
12	F/53	14	R	Octr	300	5	1	GH	Octr	300	3
13	F/36	25	—	Octr	300	6	1	GH, PRL	Lanr	60	12
14	F/59	12	L	Octr	300	7	1	GH, PRL	Octr LAR	20	5
15	M/38	16	—	Octr	500	3	1	GH, PRL	Lanr	90	3
16	F/64	31	—	Octr	300	13	2	GH, TSH	Octr	300	17
17	F/36	8	—	Octr	1500	6	1	GH	Octr LAR	30	72
18	F/49	26	R	Octr	300	13	1	GH, α-SU	Lanr	60	7
19	M/42	30	R	Octr	300	9	2	GH, PRL, α-SU	Octr	300	36
20	F/39	30	—	Octr	300	5	2	GH, PRL	Octr	300	4
21	M/15	<10	R	Lanr	60	52	2	GH, α-SU	Lanr	60	33
22	F/35	25	L	Octr	1500	10	2	GH, PRL	Octr	1500	3
23	F/19	24	L	Octr	1500	5	2	GH, PRL	Octr	1500	4
24	M/41	22	L	Lanr AG	90	4	1	GH, PRL	Lanr	60	5

Age: age at diagnosis. Diameter: maximal diameter in mm. Invasion: L/R = left/right cavernous sinuses. Treatment/Dose: Octr: octreotide (µg/day), Lanr: lanreotide (mg/month), Octr LAR: octreotide LAR (mg/month), Lanr AG: lanreotide autogel (mg/month). Surgery: 1 = gross total resection, 2 = debulking. PRL, prolactin; ACTH, adrenocorticotropin; TSH, thyrotropin; α-SU, α-subunit.

quantile–quantile plots and the Kolmogorov–Smirnov test, showing that the distribution was non-normal.

Therefore, the data were described using the trimmed mean (χ_t) with a trimming factor of 0.2. The standard error (Se_w) of the distribution of the trimmed means was calculated using the Winsorised variance (S_w^2) of the sample for a 95% confidence interval. Due also to the deviation from the normal distribution, GH and IGF-I values during SSA treatment, before and after surgery were compared using the percentile t bootstrap method for trimmed means, offering a more robust and unbiased appreciation of the difference between the means (6, 7). Chi-squared tests were also used to compare the numbers of patients achieving safe IGF-I levels under SSAs before and after surgery. Data analysis was performed with the R statistical software (8), with the additional Rand–Wilcox–Randfunv package for the standard error and bootstrap routines (9).

Results

The study population consisted of 24 acromegalic patients. The patients' demographic and disease characteristics are shown in Table 1. The mean durations of SSA treatment before and after surgery were 7.4 ± 10.0 and 10.6 ± 15.9 months ($P = \text{NS}$) respectively.

GH responses

The GH responses before and after surgery and SSAs are shown in Fig. 1 and Table 2. Lowest pretreatment GH values at t0 showed a wide range (2.6–150 $\mu\text{g/l}$) with a mean value of 22.2 $\mu\text{g/l}$ (Se_w : 3.6). Nadir GH levels were higher than 2 $\mu\text{g/l}$ in all patients at t0. At the end of the first SSA treatment period (t1), nadir GH levels were significantly lowered to a mean value

of 6.2 $\mu\text{g/l}$ (Se_w : 1.5, range 0.4–35.7 $\mu\text{g/l}$). Of the 24 patients, seven (29%) had a nadir GH less than 2 $\mu\text{g/l}$. After surgery, and following a washout period, the mean nadir GH was 6.7 (Se_w : 0.8, range 0.9–32.1 $\mu\text{g/l}$). Only three patients (12.5%) had nadir GH levels of less than 2 $\mu\text{g/l}$. During the second SSA treatment period, GH level nadirs were further decreased to a mean of 2 (Se_w : 0.7) $\mu\text{g/l}$ (range 0.2–18.6 $\mu\text{g/l}$) and GH levels were normalized in 13 patients (54%). The nadir GH values achieved during SSA treatment were significantly lower after surgery than before ($P < 0.01$). Taking patients individually, cut-off GH values of 2 $\mu\text{g/l}$ were achieved in 29.2% of patients at t1, and in 54.2% of patients at ts1. The mean (χ_t) reduction in GH with SSAs before surgery was 69% (Se_w : 6.9), which was similar to that obtained with the postoperative SSA treatment (69%, Se_w : 6.5; $P = 0.99$).

IGF-I responses

The IGF-I levels before and after surgery and SSA therapy are shown in Fig. 2 and Table 2. The mean IGF-I level at t0 was 203% (Se_w : 16, range 77–737%). This decreased to 106% of normal (Se_w : 14, range 37–647%) at t1. After surgery and washout (ts0), the mean IGF-I level was 158% (Se_w : 17, range 70–316%). The second course of SSA therapy reduced the mean IGF-I to 78% (Se_w : 9, range 20–154%). IGF-I values achieved during SSA treatment were significantly lower after surgery than before ($P < 0.01$). The number of patients who achieved safe IGF-I levels during SSAs was significantly higher after surgery. At t1, 11/24 (46%) patients achieved normal IGF-I levels, which rose to 18/23 (78%) patients at ts1 (χ^2 test, $P = 0.047$).

Figure 1 Box and whisker plots of GH levels (logarithmic) at the four time points. The box plots represent the median and the interquartile range; the whiskers represent the extremes of data ranges. Outlying data points are plotted individually. The horizontal dashed line represents the normal 2 $\mu\text{g/l}$ cut-off value. Trimmed means are indicated under each box.

Table 2 Individual GH and IGF-1 values for all patients at the four study time points.

Patient	t0		t1		ts0		ts1	
	GH ($\mu\text{g/l}$)	IGF-I (%)	GH ($\mu\text{g/l}$)	IGF-I (%)	GH ($\mu\text{g/l}$)	IGF-I (%)	GH ($\mu\text{g/l}$)	IGF-I (%)
1	15.5	164	5.7	168	5.6	—	0.6	—
2	30	131	17.8	107	26.3	82	3.9	81
3	10	—	1.4	526	4.7	89	0.6	105
4	35.1	263	2.7	105	6	316	2.9	150
5	16	227	1	59	8.2	150	1.5	80
6	62	—	9.8	169	6.2	184	2.9	92
7	34	258	1.13	132	4.5	—	0.2	65
8	16.8	190	12	118	6.6	168	2.7	82
9	12.9	211	5.6	200	7.4	253	1.6	74
10	10	179	3.4	74	1.3	—	0.2	42
11	50	133	0.7	117	1.1	129	1	48
12	21.8	180	6.7	62	9.1	84	1.7	44
13	48	—	10.3	82	8	144	5.5	81
14	7.9	164	0.8	37	5.8	76	0.2	34
15	9.3	737	5.3	647	0.9	90	0.4	100
16	2.6	85	0.4	58	3.1	70	0.56	20
17	27.3	300	16.1	136	10.1	—	2.5	141
18	150	250	3.2	77	6.2	106	0.6	27
19	28.5	139	9	147	10	122	12	154
20	12	112	1.9	68	3.6	74	0.3	58
21	26.1	184	35.7	63	11	197	5.5	99
22	35.8	173	17.7	95	32.1	—	18.6	94
23	11.57	77	9.9	56	9.4	74	7.5	47
24	22.5	240	10.6	144	6.38	182	2.9	105

t0: data at diagnosis. t1: data at the end of the preoperative SSAs trial. ts0: data after surgical debulking. ts1: data at the end of the postoperative SSAs trial. IGF-I values are expressed as % of upper normal limit. GH cut-off value: 2 $\mu\text{g/l}$. IGF-I cut-off value: 100%.

Discussion

The optimal choice of treatment for acromegalic patients with varying disease severity has been a subject of continuing discussion. Surgical treatment allows the complete removal of the adenoma in 50–70% of cases, and may definitively cure the patient. It follows, however, that in a sizeable proportion of cases, complete removal of the adenoma is not possible, due to extrasellar extension or invasion of the tumor. Bone and/or dural invasion or intracavernous extension of the tumor reduces the surgical cure rate in acromegaly. As macroadenomas represent 60–80% of GH-secreting adenomas, this is a significant therapeutic challenge (5). Primary medical treatment is considered an adjunct to or an alternative to surgery in patients with difficult-to-resect tumors. SSAs, such as octreotide and lanreotide, often in their long-acting depot formulations, are a useful option to achieve clinical improvements and potentially shrink tumors. These compounds often allow good control of GH secretion in patients not cured by surgery or in cases where surgery is contraindicated (1, 5). The GH antagonist, pegvisomant is also useful in patients who have an inadequate response to SSA treatment (10, 11). The therapeutic value of investigational agents, such as chimerical compounds that act on somatostatin and dopamine receptors, remains to be proven. Radiotherapy is third-line therapy when GH secretion is not sufficiently controlled by surgery and medical treatment, but is of limited use due to the potential for long-term side effects resulting from the irradiation of neighboring structures. As long-term treatment by SSAs permits the normalization of GH and IGF-I in a substantial

Figure 2 Box and whisker plots of IGF-I levels (logarithmic) at the four time points. Data are expressed as a percentage of the upper limit of normal values, normalized for age and sex for each assay. The box plots represent the median and the interquartile range; the whiskers represent the extremes of data ranges. Outlying data points are plotted individually. The horizontal dashed line represents the normal 100% cut-off value. Trimmed means are indicated under each box.

number of cases (40–60%) (12), some physicians may opt to treat patients suffering from extrasellar macroadenomas with SSAs when compression of adjoining structures is not present (12–17). Whether or not surgery improves the outcome of medical therapy with SSAs has not been studied previously. In studies of octreotide as primary treatment compared with patients who had undergone pituitary surgery or irradiation and who were receiving octreotide as second-line treatment, octreotide was equally effective (14). We hypothesized that by reducing tumor mass and decreasing basal GH secretion, the subsequent control of GH and IGF-I levels with SSAs could be improved. This hypothesis is consistent with long-term trials that show a better control of GH and IGF-I with SSAs when initial GH levels are lower (12). Patient inclusion for our study was facilitated by the fact that most acromegalic patients who undergo surgery at our centers are pretreated with SSAs for a period of at least 3 months to improve general health and facilitate surgical adenoma resection (18). The results of our study suggests that surgical reduction of the pituitary tumor mass can enhance the possibility of achieving postoperative hormonal control with SSA treatment. In this series, preoperative SSA therapy was associated with adequate GH and IGF-I responses in approximately 29 and 46% of patients respectively. In the case of GH, this response rate is lower than would be expected from published series, but is not surprising given that patients were suffering from large, invasive or difficult-to-resect tumors. Of the 17 patients who did not normalize GH values with preoperative medical therapy, six achieved normal GH levels with postoperative SSA treatment. Of the 13 patients who did not normalize IGF-I values with preoperative medical therapy, seven achieved normal IGF-I levels with postoperative SSA therapy. The magnitude of the decrease in GH with SSA therapy following surgical debulking was virtually identical to that seen before surgery. This indicates that surgical debulking did not have a qualitative impact on the responsiveness of GH adenoma cells; rather, these results suggest that the magnitude of the effect of SSA on reducing GH secretion in acromegaly is relatively fixed. Thus, a reduction in the baseline GH secretion by surgically debulking increases the likelihood that further reductions in GH secretion achieved by SSAs would bring patients toward acceptable hormonal control, and potentially reduce excess mortality.

In conclusion, this retrospective study shows that in patients with tumors that were not successfully removed surgically and in whom primary medical therapy was unable to produce hormonal control, gross total resection or debulking of the tumor increases the probability of achieving hormonal control with postoperative SSA administration. Even if surgery is unable to cure acromegaly or qualitatively alter the

response to SSAs, it can permit a higher percentage of patients to attain safe levels of GH and IGF-I with subsequent medical therapy.

References

- Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J & Giustina A. Acromegaly Treatment Consensus Workshop Participants. Guidelines for acromegaly management. *Journal of Clinical Endocrinology and Metabolism* 2002 **87** 4054–4058.
- Fahlbusch R, Honegger J & Buchfelder M. Surgical management of acromegaly. *Endocrinology and Metabolism Clinics of North America* 1992 **21** 669–692.
- Freda PU. Somatostatin analogs in acromegaly. *Journal of Clinical Endocrinology and Metabolism* 2002 **87** 3013–3018.
- Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P, Charbonnel B, Cortet C, Delemer B, Escobar-Jimenez F, Foubert L, Gaztambide S, Jockenhoevel F, Kuhn JM, Leclerc J, Lorcay Y, Perlemuter L, Prestele H, Roger P, Rohmer V, Santen R, Sassolas G, Scherbaum WA, Schopohl J, Torres E, Varela C, Villamil F & Webb SM. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. *Clinical Endocrinology* 2000 **53** 577–586.
- Sheppard MC. Primary medical therapy for acromegaly. *Clinical Endocrinology* 2003 **58** 387–399.
- Wilcox RR. *Fundamentals of Modern Statistical Methods*, New York: Springer, 2001.
- Yuen KK. The two sampled trimmed *t* for unequal population variances. *Biometrika* 1974 **61** 165–170.
- Ihaka R & Gentleman R. R: a language for data analysis and graphics. *Journal of Computational and Graphical Statistics* 1996 **5** 299–314.
- Wilcox RR. *Introduction to Robust Estimation and Hypothesis Testing*. San Diego, CA: Academic Press, 1997.
- Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. *New England Journal of Medicine* 2000 **342** 1210–1211.
- van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Javis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. *Lancet* 2001 **358** 1754–1759.
- Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA & Wardlaw JM. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. *Journal of Clinical Endocrinology* 2002 **87** 4554–4563.
- Vance ML & Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the international multicenter acromegalic study group. *Archives of Internal Medicine* 1991 **151** 1573–1578.
- Newman CB, Melmed S, George A, Torigan D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L & Kleinberg DL. Octreotide as primary therapy for acromegaly.

- Journal of Clinical Endocrinology and Metabolism* 1998 **83** 3034–3040.
- 15 Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I & Lombardi G. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. *Journal of Clinical Endocrinology and Metabolism* 2001 **86** 2779–2786.
- 16 Baldelli R, Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G & Tamburrano G. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). *Journal of Clinical Endocrinology and Metabolism* 2000 **85** 4099–4103.
- 17 Ayuk J, Stewart SE, Stewart PM & Sheppard MC. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. *Journal of Clinical Endocrinology and Metabolism* 2002 **87** 4142–4146.
- 18 Stevenaert A & Beckers A. Presurgical octreotide treatment in acromegaly. *Metabolism* 1996 **45** (8 Suppl 1) 72–74.
-

Received 5 August 2004

Accepted 5 October 2004